Strides Pharma Science Limited (STAR.BO)
INR 702.0
(1.56%)
INR 702.0
(1.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 23.25 Billion INR | -14.69% |
| 2022 | 27.26 Billion INR | -4.49% |
| 2021 | 28.54 Billion INR | 28.43% |
| 2020 | 22.22 Billion INR | 8.28% |
| 2019 | 20.52 Billion INR | -28.34% |
| 2018 | 28.64 Billion INR | 26.08% |
| 2017 | 22.71 Billion INR | -16.15% |
| 2016 | 27.09 Billion INR | -16.52% |
| 2015 | 32.45 Billion INR | 338.54% |
| 2014 | 7.4 Billion INR | 134.58% |
| 2013 | 3.15 Billion INR | -78.43% |
| 2012 | 14.62 Billion INR | -39.84% |
| 2011 | 24.3 Billion INR | 45.52% |
| 2010 | 16.7 Billion INR | 22.31% |
| 2009 | 13.65 Billion INR | 9.69% |
| 2008 | 12.45 Billion INR | 14.69% |
| 2007 | 10.85 Billion INR | 111.07% |
| 2006 | 5.14 Billion INR | 50.17% |
| 2005 | 3.42 Billion INR | 75.68% |
| 2004 | 1.94 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 20.84 Billion INR | 633.47% |
| 2024 Q1 | 2.96 Billion INR | -87.23% |
| 2023 FY | 23.25 Billion INR | -14.69% |
| 2023 Q4 | 23.25 Billion INR | 612.73% |
| 2023 Q1 | 3.66 Billion INR | -86.54% |
| 2023 Q3 | 3.26 Billion INR | -87.9% |
| 2023 Q2 | 26.95 Billion INR | 634.94% |
| 2022 Q3 | 1.26 Billion INR | -95.78% |
| 2022 FY | 27.26 Billion INR | -4.49% |
| 2022 Q1 | 1.87 Billion INR | -93.44% |
| 2022 Q2 | 30.04 Billion INR | 1503.92% |
| 2022 Q4 | 27.26 Billion INR | 2049.03% |
| 2021 Q3 | 4.19 Billion INR | -82.46% |
| 2021 FY | 28.54 Billion INR | 28.43% |
| 2021 Q1 | 2.79 Billion INR | -87.44% |
| 2021 Q2 | 23.93 Billion INR | 757.27% |
| 2021 Q4 | 28.54 Billion INR | 579.98% |
| 2020 Q4 | 22.22 Billion INR | 633.8% |
| 2020 Q3 | 3.02 Billion INR | -85.58% |
| 2020 Q2 | 21 Billion INR | 504.47% |
| 2020 Q1 | 3.47 Billion INR | -83.07% |
| 2020 FY | 22.22 Billion INR | 8.28% |
| 2019 Q4 | 20.52 Billion INR | 396.14% |
| 2019 Q1 | 7.91 Billion INR | -72.35% |
| 2019 Q2 | 18.66 Billion INR | 135.65% |
| 2019 FY | 20.52 Billion INR | -28.34% |
| 2019 Q3 | 4.13 Billion INR | -77.83% |
| 2018 Q4 | 28.64 Billion INR | 319.26% |
| 2018 Q3 | 6.83 Billion INR | -73.87% |
| 2018 Q2 | 26.14 Billion INR | 302.46% |
| 2018 Q1 | 6.49 Billion INR | -71.4% |
| 2018 FY | 28.64 Billion INR | 26.08% |
| 2017 Q4 | 22.71 Billion INR | 51.87% |
| 2017 FY | 22.71 Billion INR | -16.15% |
| 2017 Q3 | 14.95 Billion INR | -50.81% |
| 2017 Q2 | 30.4 Billion INR | 84.11% |
| 2017 Q1 | 16.51 Billion INR | -39.04% |
| 2016 Q3 | 14.4 Billion INR | -55.19% |
| 2016 Q4 | 27.09 Billion INR | 88.09% |
| 2016 Q2 | 32.14 Billion INR | 111.72% |
| 2016 FY | 27.09 Billion INR | -16.52% |
| 2016 Q1 | 15.18 Billion INR | -53.21% |
| 2015 Q4 | 32.45 Billion INR | 428.36% |
| 2015 Q3 | 6.14 Billion INR | -68.9% |
| 2015 Q2 | 19.75 Billion INR | 178.93% |
| 2015 Q1 | 7.08 Billion INR | -4.31% |
| 2015 FY | 32.45 Billion INR | 338.54% |
| 2014 FY | 7.4 Billion INR | 134.58% |
| 2014 Q4 | 7.4 Billion INR | 0.0% |
| 2014 Q1 | 6.32 Billion INR | 0.0% |
| 2013 FY | 3.15 Billion INR | -78.43% |
| 2012 FY | 14.62 Billion INR | -39.84% |
| 2011 FY | 24.3 Billion INR | 45.52% |
| 2010 FY | 16.7 Billion INR | 22.31% |
| 2009 FY | 13.65 Billion INR | 9.69% |
| 2008 FY | 12.45 Billion INR | 14.69% |
| 2007 FY | 10.85 Billion INR | 111.07% |
| 2006 FY | 5.14 Billion INR | 50.17% |
| 2005 FY | 3.42 Billion INR | 75.68% |
| 2004 FY | 1.94 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | -954.9 Million INR | 2535.542% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 9447.965% |
| Sigachi Industries Limited | 859.94 Million INR | -2604.462% |
| Bal Pharma Limited | 1.26 Billion INR | -1740.591% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 659.997% |
| Medico Remedies Limited | 78.67 Million INR | -29460.087% |
| Lasa Supergenerics Limited | 205.79 Million INR | -11200.828% |
| Venus Remedies Limited | -267.7 Million INR | 8787.706% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 2569.419% |
| Alpa Laboratories Limited | 35.36 Million INR | -65666.451% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -277.714% |
| Shilpa Medicare Limited | 9.06 Billion INR | -156.43% |
| Aarti Drugs Limited | 5.54 Billion INR | -319.166% |
| Lupin Limited | 17.19 Billion INR | -35.276% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -529.708% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -494.504% |
| Windlas Biotech Limited | -273.04 Million INR | 8617.796% |
| Suven Life Sciences Limited | -1.63 Billion INR | 1524.451% |
| Eris Lifesciences Limited | 13.8 Billion INR | -68.451% |
| Valiant Laboratories Limited | -295.03 Million INR | 7982.87% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -724.365% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | -131.897% |
| Ipca Laboratories Limited | 11.41 Billion INR | -103.737% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 2108.806% |
| Achyut Healthcare Limited | -3.74 Million INR | 620948.639% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 132.092% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -604.981% |
| RPG Life Sciences Limited | -364.7 Million INR | 6477.019% |
| Mankind Pharma Limited | -9.9 Billion INR | 334.73% |
| Laurus Labs Limited | 24.38 Billion INR | 4.624% |
| Piramal Pharma Limited | 42.27 Billion INR | 44.988% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -50227.822% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 26.934% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -501.593% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 642.721% |
| Unichem Laboratories Limited | 931.91 Million INR | -2395.61% |
| Sequent Scientific Limited | 4.17 Billion INR | -456.57% |
| Novartis India Limited | -5.89 Billion INR | 494.782% |
| Wanbury Limited | 1.1 Billion INR | -2003.04% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -15941.959% |
| Wockhardt Limited | 18.27 Billion INR | -27.296% |
| Themis Medicare Limited | 764.96 Million INR | -2940.28% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 1773.249% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 14.092% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 918.142% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | -80.105% |
| Divi's Laboratories Limited | -39.77 Billion INR | 158.479% |
| NATCO Pharma Limited | -5.81 Billion INR | 499.811% |
| Gufic Biosciences Limited | 3.19 Billion INR | -628.074% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 2211.776% |
| Ind-Swift Limited | 9.5 Billion INR | -144.589% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 1090.502% |
| FDC Limited | -57.75 Million INR | 40370.45% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -1103.204% |
| Granules India Limited | 9.28 Billion INR | -150.431% |
| Medicamen Biotech Limited | 160.31 Million INR | -14406.967% |
| Alkem Laboratories Limited | -1.6 Billion INR | 1545.072% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 563.985% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 126181.481% |
| Brooks Laboratories Limited | 49.48 Million INR | -46898.06% |
| Megasoft Limited | 1.28 Billion INR | -1709.105% |
| ZIM Laboratories Limited | 983.6 Million INR | -2264.467% |
| Neuland Laboratories Limited | -214.05 Million INR | 10964.808% |
| Morepen Laboratories Limited | -231.17 Million INR | 10160.383% |
| Hikal Limited | 7.96 Billion INR | -191.917% |
| Indoco Remedies Limited | 6.47 Billion INR | -259.109% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -790.424% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -19274.528% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -2283.35% |
| Hester Biosciences Limited | 2.29 Billion INR | -915.261% |